Skip to main content
Premium Trial:

Request an Annual Quote

GSK Licenses NMR Processing Software from ACD/Labs

NEW YORK, June 13 (GenomeWeb News) - Advanced Chemistry Development (ACD/Labs) said last week that GlaxoSmithKline will deploy its NMR Prediction and Processing software modules across its worldwide discovery research centers.

Under the agreement, scientists at GSK research centers in Europe and the US will use ACD/Labs NMR Processors for processing and analysis, as well as the ACD/CNMR Predictor for calculating chemical shifts and coupling constants for 13C NMR spectra. ACD/2D NMR Manager will also be installed at various locations to provide specialists with 2D NMR verification capabilities, the company said.

ACD/Combi NMR will also be installed at GSK's Stevenage, UK, and Research Triangle Park, NC, sites.

Financial terms for the licensing agreement were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.